Kazia Therapeutics (KZIA) Net Income (2009 - 2011)

Kazia Therapeutics (KZIA) posted Net Income of -$926122.0 for Q4 2011, up 81.99% on a QoQ basis from -$5.1 million in Q4 2010, and up 81.99% year-over-year from -$508884.2 in Q4 2010.

Kazia Therapeutics (KZIA) has 3 years of Net Income data on file, last reported at -$926122.0 in Q4 2011.

  • In Q4 2011, Net Income rose 81.99% year-over-year to -$926122.0; the TTM figure through Dec 2025 stood at $0.0 (changed 0.0% YoY), while the FY2025 annual figure was -$13.3 million, up 24.87% from the prior year.
  • Net Income advanced to -$926122.0 in Q4 2011, from -$5.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$926122.0 in Q4 2011 and bottomed at -$5.8 million in Q4 2009.
  • A 3-year average of -$4.0 million and a median of -$5.1 million in 2010 frame the typical range for Net Income.
  • Annual changes were most pronounced in 2010 — Net Income increased 11.52% — and 2011, when it soared 81.99%.
  • Year by year, Net Income stood at -$5.8 million in 2009, then climbed by 11.52% to -$5.1 million in 2010, then soared by 81.99% to -$926122.0 in 2011.
  • The last three Net Income figures came in at -$926122.0 (Q4 2011), -$5.1 million (Q4 2010), and -$5.8 million (Q4 2009), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Kazia Therapeutics 1.55 Bn 1.55 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2011 -926,122.02
Dec 31, 2010 -5.14 Mn
Dec 31, 2009 -5.81 Mn